regorafenib + nivolumab + FOLFOX chemotherapy with oxaliplatin

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Esophagogastric Cancer

Conditions

Esophagogastric Cancer, HER2-Negative

Trial Timeline

Feb 11, 2021 → Feb 1, 2027

NCT ID

NCT04757363

About regorafenib + nivolumab + FOLFOX chemotherapy with oxaliplatin

regorafenib + nivolumab + FOLFOX chemotherapy with oxaliplatin is a phase 2 stage product being developed by Bristol Myers Squibb for Esophagogastric Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04757363. Target conditions include Esophagogastric Cancer, HER2-Negative.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04757363	Phase 2	Active	Feb 11, 2021	Feb 1, 2027	Esophagogastric Cancer

Competing Products

6 competing products in Esophagogastric Cancer

See all competitors

Product	Company	Stage	Hype Score
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLO	Daiichi Sankyo	Phase 1/2	39
Pembrolizumab + Trastuzumab + FLOT	Merck	Phase 2	39
bevacizumab + capecitabine + cisplatin + Epirubicin + Lapatinib	Roche	Phase 2/3	34
Capecitabine + Epirubicin + AMG 102 + Cisplatin + Placebo	Amgen	Phase 1/2	32
Sacituzumab govitecan	Gilead Sciences	Phase 1/2	32
18F-BMS-986229 Injection + IV 18F-BMS-986229	Bristol Myers Squibb	Pre-clinical	26